Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Quickwork Launches Fully Self-Managed Integration Infrastructure for the AI Era
-
T7X to Present at IMN Real Estate Family Office and Private Wealth West, Introducing a New Path Forward for Real Estate Capital Formation
-
Regulatory release no. 8 - 2026: Completion of InstallatørGruppen A/S' Initial Public Offering
-
ING appoints Hilde Garssen to the Management Board Banking
-
Pulsar Helium Announces Expanded Land Position at Topaz, and Provides a Project Technical Update
-
IQE and Tower Semiconductor Announce Multi-year InP epiwafer Supply Agreement
-
VAALCO Energy, Inc. Announces Exciting Operational Update in Offshore Gabon and in Egypt
-
Magnera Announces the Sale of Its Caerphilly, United Kingdom Operations
-
IQE and Tower Semiconductor Announce Multi-year InP epiwafer Supply Agreement
-
LTP Secures Australian Financial Services Licence (AFSL) to Bridge Institutional Capital with Tokenized Real-World Assets
-
Hilde Garssen to step down from KPN and join ING
-
BW Offshore: Company presentation
-
NBPE Announces Transaction in Own Shares
-
SHELL PLC FIRST QUARTER 2026 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS
-
Transaction in Own Shares
-
Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development
-
Regulatory release no. 7 - 2026: No termination or withdrawal of InstallatørGruppen A/S' initial public offering
-
Schneider Electric and Hon Hai Technology Group (Foxconn) announce strategic collaboration to accelerate next-generation AI data centers
-
WORLDLINE : Completion of reverse share split - Press release
-
BW Offshore: BW Opal achieves Interim Performance Test milestone
-
Sampo plc’s share buybacks week 24/2026
-
Toobit Boosts Solana Yields to 60% APR for Limited Time
-
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
-
2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
-
Energy security tops political agendas as prospects for offshore wind recovery gain momentum, TGS | 4C report finds
-
Start of Day Message
-
Banqup Group Announces Strategic Simplification Plan and Launch of Process to Explore Strategic Alternatives
-
Aktsiaselts Infortar own share acquisition transactions
-
Vallourec Geothermal Deep Dive
-
Dassault Systèmes successfully issues €1 billion in bonds and refinances its revolving credit facility
-
Mowi ASA (OSE: MOWI): 2026 Salmon Farming Industry Handbook
-
Questerre successfully tests HCCO® Technology in a Commercial-Sized Vessel at PX Energy
-
The Mom’s Choice Awards Names GROWNSY’s Portable Bottle Warmer and SniffEase Spa 3-in-1 Nasal Aspirator Among the Best in Family-Friendly Products
-
Crypto News Today: AlphaPepe Presale Stage 17 Sold Out as Dogecoin Price Prediction Eyes $1.00
-
Perseus Mining Increases Share Buy-Back from AUD100M to AUD 150M
-
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
-
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
-
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
-
Author Fari Presents Cambodia's Path to Peace and Stability in New Book on Hun Sen's Leadership
-
Author Fari Presents Cambodia's Path to Peace and Stability in New Book on Hun Sen's Leadership
-
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
-
Modat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph
-
Orbs Launches On-Chain Execution Infrastructure for Institutional Crypto Trading
-
Modat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph
-
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual
-
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at E
-
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
-
Bitcoin Meets AI Trading: AIXAlpha Launches Free AI Strategy Contracts with Daily Settlement
-
Over 100 Organizations Thank America’s Blood Donors on World Blood Donor Day
-
Ruvi AI (RUVI) Announces Phase 3 Has Reached 90% Sellout as Investors Race to Secure Remaining Tokens at $0.02

